List view / Grid view
Data shared at the 2023 American Society of Retina Specialists…
Data shared at the 2023 American Society of Retina Specialists (ASRS) Annual Meeting will reveal new clinical and real-world evidence for the first bispecific antibody (bsAb) approved for the eye.
A Phase III trial for the only therapy approved for…
A Phase III trial for the only therapy approved for both relapsing and primary progressive multiple sclerosis (MS) met its clinical endpoints, Genentech has announced.
European approval of the bispecific antibody treatment has the potential…
European approval of the bispecific antibody treatment has the potential to change the current standard of care in diffuse large B-cell lymphoma (DLBCL).
The US Food and Drug Administration (FDA) has approved the…
The US Food and Drug Administration (FDA) has approved the first bispecific antibody with a fixed-duration treatment in (R/R) diffuse large B-cell lymphoma (DLBCL).
A first-line B-cell lymphoma treatment shown to reduce the risk…
A first-line B-cell lymphoma treatment shown to reduce the risk of disease progression or relapse by 27 percent has been approved by the FDA.
IMbrave050 is the first Phase III study to show a…
IMbrave050 is the first Phase III study to show a cancer immunotherapy combo reduced risk of disease recurrence for early-stage hepatocellular carcinoma.
Xofluza® offers the first novel mechanism of action for an…
Xofluza® offers the first novel mechanism of action for an influenza antiviral to be approved by the European Commission in almost 20 years.
Glofitamab for relapsed or refractory large B-cell lymphoma has been…
Glofitamab for relapsed or refractory large B-cell lymphoma has been granted priority review by the US Food and Drug Administration (FDA).
Roche’s Vabysmo® (faricimab) has been approved in Europe as a…
Roche’s Vabysmo® (faricimab) has been approved in Europe as a four-monthly treatment for wet age-related macular degeneration and diabetic macular oedema.
New data demonstrates the long-term safety and efficacy of Evrysdi®…
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).
Roche's gantenerumab is an anti-amyloid beta antibody developed for subcutaneous…
Roche's gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were…
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
The Phase II study of Evrysdi showed significant improvements in…
The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA).
The European Commission has granted marketing authorisation to Roche’s Evrysdi™…
The European Commission has granted marketing authorisation to Roche’s Evrysdi™ (risdiplam) as a treatment for spinal muscular atrophy in infants, children and adults.
